Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune SA (NASDAQ: ACIU) announced positive proof-of-concept data for its experimental a-syn PET tracer, ACI-12589, in diagnosing Multiple System Atrophy (MSA). Conducted by Lund University, the trial showcased the ability to distinguish MSA patients from healthy individuals and other a-synucleinopathies. Dr. Oskar Hansson highlighted the breakthrough as a significant clinical advancement. The results were presented at the AD/PD Conference in Barcelona and indicate enhanced specificity and target engagement. A webinar on March 29 will further discuss these findings.
AC Immune (NASDAQ: ACIU) announced five data presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) from March 15-20, 2022, showcasing its focus on neurodegenerative diseases. Prof. Andrea Pfeifer, CEO, highlighted a significant milestone: the first in-human study of the ACI-12589 a-syn PET tracer. This research aims to enhance disease detection and prevention strategies through precision medicine. These presentations underline the company's commitment to advancing treatments for neurodegenerative diseases, potentially impacting future market performance.
AC Immune SA (NASDAQ: ACIU) revealed new interim data from its Phase 1b/2a trial for ACI-35.030, a pioneering pTau vaccine for early Alzheimer's disease. Findings show significant antibody induction specific to pathological pTau, with a favorable safety profile noted in all dosage cohorts. The study has been expanded to 24 participants to gather more data. CEO Andrea Pfeifer stated these results support ongoing late-stage development, potentially reshaping AD treatment towards earlier interventions alongside advanced diagnostics.
AC Immune SA (NASDAQ: ACIU) announced strong preclinical results for its optimized ACI-24 vaccine targeting neurotoxic pyroGlu-Abeta variants, crucial in Alzheimer's disease. The data, published in Brain Communications, highlights ACI-24's robust immune response in non-human primates and mice, outperforming other tested vaccines. The company plans to advance ACI-24 into clinical development for Alzheimer's and Down syndrome-related Alzheimer's disease in 2022. AC Immune is positioned as a leader in developing active vaccines for neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU), a leader in precision medicine for neurodegenerative diseases, will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. CEO Prof. Andrea Pfeifer will engage in a fireside chat on February 16 at 8:00 am ET, discussing the company’s strategic plans and seven upcoming clinical readouts. The event will be available via webcast on their website. AC Immune is advancing a robust pipeline with ten therapeutic and three diagnostic candidates, focusing on diseases like Alzheimer’s and Parkinson’s.
AC Immune SA (NASDAQ: ACIU) has received approximately USD 1.5 million in grants from The Michael J. Fox Foundation for Parkinson’s Research. This funding will support the development of innovative small molecules aimed at inhibiting alpha-synuclein (a-syn) aggregation and NLRP3 inflammasome activation in Parkinson’s disease. The grants enhance AC Immune's research capabilities and expand its portfolio, including an anti-a-syn vaccine and a novel imaging tracer, showcasing its commitment to precision medicine in treating neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) presented promising interim Phase 1b/2a trial results for ACI-35.030, a vaccine targeting pathological tau in Alzheimer's disease, at the 14th CTAD conference. The data shows significant antibody induction against pTau and its aggregated forms, indicating strong immunogenicity. Safety data revealed no clinically relevant concerns. The trial has expanded to 24 participants to support late-stage development. The results suggest potential for early intervention in Alzheimer's treatment, with further data expected from the ongoing study.
AC Immune announced positive topline results from its Phase 2 Lauriet study of semorinemab, an anti-Tau monoclonal antibody for mild-to-moderate Alzheimer’s disease (AD). The study achieved a 43.6% reduction in cognitive decline at week 49 as measured by the ADAS-Cog11 scale, confirming the treatment's efficacy across various subgroups. However, it did not meet the second co-primary endpoint related to daily living activities. Safety results were positive, indicating semorinemab had an acceptable safety profile with no unexpected adverse events. The ongoing open-label study aims to further assess long-term effects.
AC Immune SA (NASDAQ: ACIU) reported progress in its clinical trials and financial results for Q3 2021, achieving its first positive cognitive results for a Tau-targeting monoclonal antibody in Alzheimer’s disease. The Phase 2 Lauriet trial showed a statistically significant 43.6% reduction in cognitive decline. The company enhanced its portfolio through the acquisition of an alpha-synuclein vaccine candidate. Financially, AC Immune holds CHF 188.6 million in cash, sufficient to fund operations through Q1 2024, despite a net loss of CHF 15.9 million for the quarter.
AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company based in Switzerland, is extending its research partnership with the University of Pennsylvania focused on TDP-43 proteinopathies. The collaboration aims to explore the mechanisms of TDP-43 misfolding and cell-to-cell transmission, which are important in neurodegenerative diseases like ALS and Alzheimer's. The initial research demonstrated distinct TDP-43 species affecting disease progression. AC Immune is also advancing its lead anti-TDP-43 antibody and developing a PET tracer for diagnostics.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
